<DOC>
	<DOCNO>NCT00882583</DOCNO>
	<brief_summary>Primary Objective Phase I 1 . To determine maximally tolerate dose ( MTD ) daily Oral dasatinib combination cetuximab/RT Cohort A , patient AJCC stage II ( T2N0 ) III ( T1-2N1 ) SCCHN oral cavity , oropharynx , T2N0 hypopharynx , T2N0-1 supraglottic larynx . 2 . To determine MTD daily oral dasatinib combination cisplatin/cetuximab/RT Cohort B , patient AJCC stage III ( T3N0-1 ) IV ( T1-4N2-3M0 , T4N0-1M0 ) squamous cell carcinoma oral cavity , oropharynx , hypopharynx , larynx . Primary Objectives Phase II 3 . To estimate objective tumor response rate toxicity Patients treat expanded Cohort A B .</brief_summary>
	<brief_title>A Study Dasatinib , Cetuximab Radiation With Without Cisplatin HNSCC</brief_title>
	<detailed_description>Primary Objective Phase I 1 . To determine maximally tolerate dose ( MTD ) daily Oral dasatinib combination cetuximab/RT Cohort A , patient AJCC stage II ( T2N0 ) III ( T1-2N1 ) SCCHN oral cavity , oropharynx , T2N0 hypopharynx , T2N0-1 supraglottic larynx . 2 . To determine MTD daily oral dasatinib combination cisplatin/cetuximab/RT Cohort B , patient AJCC stage III ( T3N0-1 ) IV ( T1-4N2-3M0 , T4N0-1M0 ) squamous cell carcinoma oral cavity , oropharynx , hypopharynx , larynx . Primary Objectives Phase II 1 . To estimate objective tumor response rate toxicity Patients treat expanded Cohort A B . Secondary Objectives Phase II 1 . To estimate 2 year disease free survival patient treat Cohorts A B . 2 . To estimate median overall survival patient treat Cohorts A B . 3 . To perform exploratory analysis biomarker expression serial sample tumor blood correlate biomarker expression response survival outcomes patient treat Cohorts A B . 4 . To estimate role 18F-FDG PET early indicator response patient treat Cohorts A B correlate clinical pathological response survival outcome .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>1 . Patients must histologically confirm operable inoperable squamous cell carcinoma OC , OP , HP , larynx prior proceed treatment . 2 . Patients must AJCC stage II ( T2N0 ) III ( T12N1 ) oral cavity , oropharynx , T2N0 hypopharynx , T2N01 supraglottic laryngeal cancer ( AJCC Fifth Edition , 1997 ) Arm A study , must AJCC stage III ( T3N01 ) IV ( T14N23M0 , T4N01M0 ) oral cavity , oropharynx , hypopharynx , glottic supraglottic laryngeal cancer Arm B study . 3 . Patients must measurable disease , . 4 . Subject , age ≥ 18 year . 5 . Performance Status ( ECOG ) 01 6 . No previous therapy tumor , include chemotherapy , radiation therapy , immunotherapy , EGFR target therapy , src direct therapy investigational agent . 7 . Adequate Organ Function . Total bilirubin ≤ 1.5 x ULN AST ALT ≤ 2.5 x ULN Alkaline phosphatase ≤ 2.5 x ULN Hepatic enzyme ( AST , ALT ) ≤ 2.5 time institutional ULN . Serum Na , K+ , Mg2+ , Phosphate Ca2+ ≥ low limit normal ( LLN ) . Serum Creatinine clearance ≥ 60 ml/min . Hemoglobin , neutrophil count , platelet , PT , PTT Grade 01 . ANC ≥ 1,500/mL Platelets ≥ 100,000 mL 8 . Concomitant medication Patient agree discontinue St. Johns Wort , proton pump inhibitor , H2 blocker , aspirin NSAIDS receive dasatinib therapy . Patient agree IV po bisphosphonates withhold first 8 week dasatinib therapy due risk hypocalcemia . 9 . Women childbearing potential ( WOCBP ) must : A negative serum urine pregnancy test ( sensitivity ≤ 25IU HCG/L ) within 72 hour prior start study drug administration . 10 . Persons reproductive potential must agree use utilize adequate method contraception throughout treatment least 4 week study drug stop . 11 . Ability understand willingness sign write informed consent , include HIPAA form accord institutional guideline . 1 . Any prior radiation clavicle 2 . Prior head neck cancer . Any prior invasive malignancy disease free interval ≤ 3 year . Nonmelanomatous carcinoma skin situ cervical dysplasia allow completely resect within three year interval completely resect prior start treatment . 3 . History allergic reaction attribute compound similar chemical biologic composition cetuximab , dasatinib agent use study . 4 . Gastrointestinal tract disease result inability take absorb oral enteral medication . 5 . Concurrent medical condition may increase risk toxicity , include : Pleural pericardial effusion grade . Cardiac Symptoms ; follow consider exclusion : Uncontrolled angina , congestive heart failure MI within ( 6 month ) . Diagnosed congenital long QT syndrome . Any history clinically significant ventricular arrhythmia ( ventricular tachycardia , ventricular fibrillation , Torsades de pointes ) . Prolonged QTc interval preentry electrocardiogram ( &gt; 450 msec ) . 6 . Subjects hypokalemia hypomagnesemia correct prior protocol treatment . 7 . History significant bleeding disorder unrelated cancer , include : Diagnosed congenital bleeding disorder ( e.g. , von Willebrand 's disease ) . Diagnosed acquire bleed disorder within one year ( e.g. , acquire antifactor VIII antibody ) . Ongoing recent ( ≤ 3 month ) significant gastrointestinal bleeding . 8 . Concomitant Medications , follow consider exclusion : 1 . Category I drug generally accept risk cause Torsades de Pointes include : ( Patients must discontinue drug 7 day prior start dasatinib ) quinidine , procainamide , disopyramide amiodarone , sotalol , ibutilide , dofetilide erythromycin , clarithromycin chlorpromazine , haloperidol , mesoridazine , thioridazine , pimozide cisapride , bepridil , droperidol , methadone , arsenic , chloroquine , domperidone , halofantrine , levomethadyl , pentamidine , sparfloxacin , lidoflazine . 2 . The concomitant use H2 blocker proton pump inhibitor dasatinib recommend . The use antacid consider place H2 blocker proton pump inhibitor patient receive dasatinib therapy . If antacid therapy need , antacid dose administer least 2 hour prior 2 hour dose dasatinib . 9 . Patient may receive prohibited CYP3A4 inhibitor . Refer section 10 concomitant medication may wish prohibit base disease/patient population . 10 . Women : unwilling unable use acceptable method avoid pregnancy entire study period least 4 week cessation study drug , positive pregnancy test baseline , pregnant breastfeed 11 . Prisoners subject compulsorily detain ( involuntarily incarcerate ) treatment either psychiatric physical ( e.g. , infectious ) illness .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>HNSCC</keyword>
	<keyword>Dasatinib</keyword>
	<keyword>Cetuximab</keyword>
	<keyword>Cisplatin</keyword>
</DOC>